Executive Order 14228 represents an escalation in the Biden administration's response to what it characterizes as an ongoing synthetic opioid crisis affecting the United States. The order builds upon Executive Order 14195 (February 1, 2025) and its subsequent amendment (Executive Order 14200), which initially imposed tariffs on Chinese products in response to what the administration describes as the failure of the People's Republic of China (PRC) to adequately address the flow of synthetic opioids, including fentanyl, from China to the United States. The administration continues to frame this issue as an "unusual and extraordinary threat" to U.S. national security, foreign policy, and economy, invoking the International Emergency Economic Powers Act (IEEPA) as the primary legal authority for these measures.
The core directive of this executive order is straightforward but significant: it doubles the previously imposed ad valorem tariffs on products from the PRC from 10 percent to 20 percent. This increase is explicitly justified in the order as a response to the administration's determination that "the PRC has not taken adequate steps to alleviate the illicit drug crisis through cooperative enforcement actions" and that the crisis described in the original executive order "has not abated." No other substantive changes to the tariff structure or affected products are mentioned in this amendment.
The implementation of this order falls under the existing framework established by the previous orders, with no new specific directives to agencies or officials mentioned. As with the previous orders, this amendment contains standard provisions clarifying that it does not impair existing legal authorities, must be implemented consistent with applicable law and available appropriations, and does not create any new legal rights or benefits. The doubling of tariffs signals the administration's willingness to use increasingly punitive economic measures to pressure China on drug enforcement cooperation, potentially raising the stakes in U.S.-China relations while attempting to address what the administration portrays as a continuing public health and security crisis related to synthetic opioids.